Market Cap 7.45B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,749,400
Avg Vol 3,161,734
Day's Range N/A - N/A
Shares Out 105.29M
Stochastic %K 44%
Beta N/A
Analysts Strong Sell
Price Target $55.75

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
jollylollylondon8
jollylollylondon8 Nov. 13 at 9:09 AM
$MTSR Early morning sellers clearly don’t understand the value of the CVR; Goldman and Guggenheim put the closing value at $72.40 ish.. should move towards 72.40 before close tonight
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:21 AM
$MTSR is currently trading at $70.8, showing strong momentum as indicated by an RSI of 66.68, suggesting it's nearing overbought territory but still has room for upward movement. The price is significantly above the 30-day MA of 58.09 and the 50-day MA of 51.39, indicating a bullish trend. The recent high of $83.86 presents a key resistance level, while the low of $29.19 provides a solid support base. For a trade plan, consider entering at $71.50 to capitalize on potential upward momentum. Set a stop loss at $66.00 to manage risk. Target 1 can be set at $80.00, approaching the 60D high, and Target 2 at $83.00, just below the recent high. This plan leverages the current bullish indicators while accounting for volatility with an ATR of 4.96. Monitor the RSI closely for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
1 · Reply
friedcheeken
friedcheeken Nov. 13 at 2:11 AM
0 · Reply
BinaryLogic
BinaryLogic Nov. 13 at 2:03 AM
$RANI [Again] RANI not only fortified its balance sheet with a Cash runway to 2028 (estimated) and established a merit-based contract with Chugai (Roche is the majority owner) totaling more than $1.0B, but it also has a GLP1/2 in-progress (RT114) with a method of oral delivery (Ranipill) - contacts at NVO as noted in my prior post(s). The Company is valued at a fraction of the anticipated Chugai contract, and that does not even take into consideration the balance of its product pipeline, including a possible oral weight-loss drug. $VKTX is valued at $4.0B, $MTSR was just purchased/acquired for $10.0B, and RANI sits at a $0.3B market cap (appx) by comparison with additional verticals and a separate $1.0B agreement already locked. Multiplier upside still (IMO) from current levels.
1 · Reply
jollylollylondon8
jollylollylondon8 Nov. 13 at 12:35 AM
$MTSR Should move toward $72.40 value according to Goldman and Guggenheim for the last day of trading before closure in 14th
0 · Reply
TwongStocks
TwongStocks Nov. 12 at 9:41 PM
$MTSR NASDAQ Equity Corporate Actions Alert # 2025 - 605 Information Regarding the Merger of Metsera, Inc. (MTSR) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-605 At a special meeting to be held on November 13, 2025, the shareholders of Metsera, Inc. (MTSR) will vote to approve a merger with Pfizer, Inc. (PFE). The merger is tentatively scheduled to close November 13, 2025.
1 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
jollylollylondon8
jollylollylondon8 Nov. 12 at 6:19 PM
$MTSR And it’s likely to close this week?
0 · Reply
jollylollylondon8
jollylollylondon8 Nov. 12 at 6:19 PM
$MTSR Goldman Sachs and Guggenheim securities value the closing transaction before the CVR is paid currently at $72.48
0 · Reply
rick4u
rick4u Nov. 12 at 6:18 PM
$MTSR on fire 😉
0 · Reply
Latest News on MTSR
Pfizer to buy Metsera in deal worth up to $10 billion

Nov 10, 2025, 10:30 AM EST - 2 days ago

Pfizer to buy Metsera in deal worth up to $10 billion

PFE


Novo Nordisk shares rise after dropping Metsera bid

Nov 10, 2025, 3:05 AM EST - 3 days ago

Novo Nordisk shares rise after dropping Metsera bid

NVO


Novo CEO says its bid for Metsera is higher

Nov 6, 2025, 2:23 PM EST - 6 days ago

Novo CEO says its bid for Metsera is higher

NVO


Metsera Issues Statement in Response to Litigation Ruling

Nov 5, 2025, 7:17 PM EST - 7 days ago

Metsera Issues Statement in Response to Litigation Ruling


Pfizer preparing to raise its bid for Metsera, WSJ reports

Nov 5, 2025, 5:02 PM EST - 7 days ago

Pfizer preparing to raise its bid for Metsera, WSJ reports

PFE


The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs

Nov 5, 2025, 1:20 PM EST - 7 days ago

The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs


Novo Nordisk CEO: Confident we will close Metsera deal

Nov 5, 2025, 5:39 AM EST - 8 days ago

Novo Nordisk CEO: Confident we will close Metsera deal

NVO


Pfizer and Novo Nordisk both raise bids for Metsera

Nov 4, 2025, 12:18 PM EST - 8 days ago

Pfizer and Novo Nordisk both raise bids for Metsera

NVO PFE


Novo Nordisk says Metsera bid won't raise antitrust issues

Nov 3, 2025, 12:04 PM EST - 9 days ago

Novo Nordisk says Metsera bid won't raise antitrust issues

NVO


Metsera Issues Statement in Response to Litigation

Nov 3, 2025, 11:02 AM EST - 9 days ago

Metsera Issues Statement in Response to Litigation


Pfizer files second lawsuit against Metsera, Novo Nordisk

Nov 3, 2025, 8:07 AM EST - 9 days ago

Pfizer files second lawsuit against Metsera, Novo Nordisk

NVO PFE


Pfizer sues Metsera, Novo Nordisk over breach of merger deal

Oct 31, 2025, 4:43 PM EDT - 12 days ago

Pfizer sues Metsera, Novo Nordisk over breach of merger deal

NVO PFE


Pfizer gets US antitrust clearance for Metsera deal

Oct 31, 2025, 3:55 PM EDT - 12 days ago

Pfizer gets US antitrust clearance for Metsera deal

PFE


Pfizer could hold a Trump card in its bid for Metsera

Oct 31, 2025, 6:02 AM EDT - 13 days ago

Pfizer could hold a Trump card in its bid for Metsera

PFE


Mizuho's Holtz talks what is behind Novo's bid for Metsera

Oct 30, 2025, 6:20 PM EDT - 13 days ago

Mizuho's Holtz talks what is behind Novo's bid for Metsera


Novo: Risks Revisited And Potential Metsera Deal

Oct 30, 2025, 5:23 PM EDT - 13 days ago

Novo: Risks Revisited And Potential Metsera Deal


jollylollylondon8
jollylollylondon8 Nov. 13 at 9:09 AM
$MTSR Early morning sellers clearly don’t understand the value of the CVR; Goldman and Guggenheim put the closing value at $72.40 ish.. should move towards 72.40 before close tonight
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:21 AM
$MTSR is currently trading at $70.8, showing strong momentum as indicated by an RSI of 66.68, suggesting it's nearing overbought territory but still has room for upward movement. The price is significantly above the 30-day MA of 58.09 and the 50-day MA of 51.39, indicating a bullish trend. The recent high of $83.86 presents a key resistance level, while the low of $29.19 provides a solid support base. For a trade plan, consider entering at $71.50 to capitalize on potential upward momentum. Set a stop loss at $66.00 to manage risk. Target 1 can be set at $80.00, approaching the 60D high, and Target 2 at $83.00, just below the recent high. This plan leverages the current bullish indicators while accounting for volatility with an ATR of 4.96. Monitor the RSI closely for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
1 · Reply
friedcheeken
friedcheeken Nov. 13 at 2:11 AM
0 · Reply
BinaryLogic
BinaryLogic Nov. 13 at 2:03 AM
$RANI [Again] RANI not only fortified its balance sheet with a Cash runway to 2028 (estimated) and established a merit-based contract with Chugai (Roche is the majority owner) totaling more than $1.0B, but it also has a GLP1/2 in-progress (RT114) with a method of oral delivery (Ranipill) - contacts at NVO as noted in my prior post(s). The Company is valued at a fraction of the anticipated Chugai contract, and that does not even take into consideration the balance of its product pipeline, including a possible oral weight-loss drug. $VKTX is valued at $4.0B, $MTSR was just purchased/acquired for $10.0B, and RANI sits at a $0.3B market cap (appx) by comparison with additional verticals and a separate $1.0B agreement already locked. Multiplier upside still (IMO) from current levels.
1 · Reply
jollylollylondon8
jollylollylondon8 Nov. 13 at 12:35 AM
$MTSR Should move toward $72.40 value according to Goldman and Guggenheim for the last day of trading before closure in 14th
0 · Reply
TwongStocks
TwongStocks Nov. 12 at 9:41 PM
$MTSR NASDAQ Equity Corporate Actions Alert # 2025 - 605 Information Regarding the Merger of Metsera, Inc. (MTSR) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-605 At a special meeting to be held on November 13, 2025, the shareholders of Metsera, Inc. (MTSR) will vote to approve a merger with Pfizer, Inc. (PFE). The merger is tentatively scheduled to close November 13, 2025.
1 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
jollylollylondon8
jollylollylondon8 Nov. 12 at 6:19 PM
$MTSR And it’s likely to close this week?
0 · Reply
jollylollylondon8
jollylollylondon8 Nov. 12 at 6:19 PM
$MTSR Goldman Sachs and Guggenheim securities value the closing transaction before the CVR is paid currently at $72.48
0 · Reply
rick4u
rick4u Nov. 12 at 6:18 PM
$MTSR on fire 😉
0 · Reply
Turbofueled
Turbofueled Nov. 12 at 6:01 PM
$LEXX exactly what I was Implying earlier! $NVO may be the one that holds the MTA but $LEXX could be very valuable to $PFE after acquiring $MTSR There could be BIG negotiating HAPPENING!!!!
0 · Reply
DrStockenstein
DrStockenstein Nov. 12 at 4:23 PM
$MTSR $PFE 🤡🤡🤡
1 · Reply
DrStockenstein
DrStockenstein Nov. 12 at 3:45 PM
$MTSR That's the real question..
0 · Reply
Turbofueled
Turbofueled Nov. 12 at 3:06 PM
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 2:44 PM
$NMRA For those who are interested in the next level weight loss drugs such as $MTSR $NVO $PFE and others, $NRMA is presenting at Stifel this afternoon. Would hope for a stock upgrade from them after presentation.
0 · Reply
olivia_white19
olivia_white19 Nov. 12 at 12:03 PM
$MTSR micro alert. Ne
0 · Reply
DreamCannonShade
DreamCannonShade Nov. 12 at 11:46 AM
$MTSR micro-cap a
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:57 AM
$MTSR is currently trading at $70.8, showing strong momentum as indicated by an RSI of 66.68, suggesting it's nearing overbought territory but still has room for upward movement. The price is significantly above the 30-day MA of 58.09 and the 50-day MA of 51.39, indicating a bullish trend. The recent high of $83.86 presents a key resistance level, while the low of $29.19 provides a solid support base. For a trade plan, consider entering at $71.50 to capitalize on potential upward momentum. Set a stop loss at $66.00 to manage risk. Target 1 can be set at $80.00, approaching the 60D high, and Target 2 at $83.00, just below the recent high. This plan leverages the current bullish indicators while accounting for volatility with an ATR of 4.96. Monitor the RSI closely for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
1 · Reply
warrants_Moon
warrants_Moon Nov. 11 at 11:35 PM
$MTVA dilution here won’t matter. Has a pipeline equivalent to $MTSR meta via should be on the radar, for everyone. This won’t be this low for long
0 · Reply
Yeueehehe
Yeueehehe Nov. 11 at 10:29 PM
$MTSR $VKTX $60 is where this will be in 1 month or less
0 · Reply
lukasgx
lukasgx Nov. 11 at 10:24 PM
$VKTX BO at 60 is a steal if you consider $MTSR final price
4 · Reply
friedcheeken
friedcheeken Nov. 11 at 10:06 PM
$PFE Trending #3 slot because people are watching scratching their heads not seeing whats happening here. 45 million shares net buy by hedge funds in Q1 and positive accumulation after that too (check in robinhood) A week and a half of volume ranging from 2-3x the average volume, seemingly accumulating not distributing. The dividend yield is 6-7% at this level which is nuts. The call option activity here is absolutely bonkers like for real the hedging for those calls alone will drive the price up (it already is). Average price target is around 30 per share without the acquisition, highest price target is 34. The PE ratio right now is about half or so of its peers. This could hit 30 this week or next easily and the $MTSR share holder meeting on Thursday to make it official could just be the catalyst that sends it there.
0 · Reply